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Human histo-blood group A transferase (AT) catalyzes the biosynthesis of oligosaccharide A antigen 
important in blood transfusion and cell/tissue/organ transplantation. This enzyme may synthesize 
Forssman antigen (FORS1) of the FORS blood group system when exon 3 or 4 of the AT mRNA is deleted 
and/or the LeuGlyGly tripeptide at codons 266–268 of AT is replaced by GlyGlyAla. The Met69Ser/Thr 
substitutions also confer weak Forssman glycolipid synthase (FS) activity. In this study, we prepared 
the human AT derivative constructs containing any of the 20 amino acids at codon 69 with and without 
the GlyGlyAla substitution, transfected DNA to newly generated COS1(B3GALNT1 + A4GALT) cells 
expressing an enhanced level of globoside (Gb4), the FS acceptor substrate, and immunologically 
examined the FORS1 expression. Our results showed that all those substitution constructs at codon 69 
exhibited FS activity. The combination with GlyGlyAla significantly increased the activity. The conserved 
methionine residue in the ABO, but not GBGT1, gene-encoded proteins may implicate its contribution 
to the separation of these genes in genetic evolution. Surprisingly, with increased Gb4 availability, 
the original human AT with the methionine residue at codon 69 was also demonstrated to synthesize 
FORS1, providing another molecular mechanism of FORS1 appearance in cancer of ordinary FORS1-
negative individuals.
Human blood group ABO system (ABO) consists of A and B antigens expressed on red blood cells (RBCs) and 
the antibodies against these antigens in the sera of individuals who do not express the antigen(s) (Landsteiner’s 
Law). The A and B antigens are oligosaccharides with the following chemical structures: GalNAcα1-3(Fucα1-2)
Gal- (A antigen) and Galα1-3(Fucα1-2)Gal- (B antigen)1,2. Functional A and B alleles at the ABO genetic locus 
encode A and B transferases (AT and BT), which catalyze the last biosynthetic reactions of A and B antigens 
by transferring an N-acetyl-d-galactosamine (GalNAc) and galactose from nucleotide-sugars UDP-GalNAc and 
UDP-galactose, respectively, to the common precursor substrate H substance (Fucα1-2Gal-). The Forssman 
system (FORS) is another blood group system with oligosaccharide Forssman antigen (FORS1) and its anti-
bodies3. Homo sapiens being a Forssman antigen-negative species4, ordinary individuals are FORS1-negative 
(FORS1−) and do not express FORS1 antigen3,5. However, there are FORS1-positive (FORS1+) individu-
als expressing FORS1 although the frequency is extremely low in the human population (rs375748588 SNP, 
MAF/Minor Allele Count: T = 0.000008/1 (ExAC), T = 0.00008/1 (GO-ESP), T = 0.00005/6 (TOPMED)). 
The International Society of Blood Transfusion (ISBT) numbered the ABO and FORS systems to be 001 
and 031, respectively. Forssman glycolipid synthase (FS) encoded by the functional allele at the GBGT1 
gene5,6 catalyzes the last biosynthetic step of FORS1-carrying penta-saccharide Forssman glycolipid (Gb5: 
1Laboratory of immunohematology and Glycobiology, Josep carreras Leukaemia Research institute (iJc), 
Campus Can Ruti, Camí de les Escoles, Badalona, Barcelona, 08916, Spain. 2Biologia Molecolare, Università 
degli Studi di Parma, Parma, 43121, Italy. 3Program of Predictive and Personalized Medicine of cancer (PMPPc), 
institut d’investigació Germans trias i Pujol (iGtP), campus can Ruti, camí de les escoles, Badalona, Barcelona, 
08916, Spain. 4Laboratory of Molecular Microbiological Science, faculty of Pharmaceutical Sciences, Hiroshima 
International University, Kure, Hiroshima, 737-0112, Japan. Miyako Yamamoto, Maria Cristina Tarasco and Emili Cid 
contributed equally. Correspondence and requests for materials should be addressed to F.Y. (email: fyamamoto@
carrerasresearch.org)
Received: 12 March 2019
Accepted: 17 June 2019
Published: xx xx xxxx
OPEN
2Scientific RepoRts |          (2019) 9:9717  | https://doi.org/10.1038/s41598-019-46029-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1′Cer) from the precursor globoside (Gb4: GalNAcβ1-3Galα1-
4Galβ1-4Glcβ1-1′Cer) by transferring a GalNAc7. Biosynthetic pathways of blood group A, B, and FORS1 anti-
gens are schematically shown in Fig. 1.
In 1990, we cloned the blood group A, B, and O allelic cDNAs, determined their nucleotide sequences, 
and correlated their sequences with the A/B antigen expression. We found that A allele-encoded AT and B 
allele-encoded BT are the same in size, but there are 4 amino acid substitutions between them8,9. They are arginine 
(Arg), glycine (Gly), leucine (Leu), and Gly in AT, and Gly, serine (Ser), methionine (Met), and alanine (Ala) in 
BT at codons 176, 235, 266, and 268. We prepared 14 AT-BT chimeras that were different at those 4 positions, hav-
ing either amino acid of AT or BT, transfected DNA from those constructs to human carcinoma of uterus HeLa 
cells expressing H substance, the precursor substrate for AT/BT, and examined the appearance of cell-surface A 
and/or B antigens. We were able to demonstrate that the amino acids at codons 266 and 268 are crucial on sugar 
specificity and enzymatic activity, whereas those at codons 235 and 176 exerted slight and no effect, respectively10. 
We also identified a single nucleotide deletion (261delG) in the majority of nun-functional O alleles9 and a single 
inactivating glycine-to-arginine substitution at codon 268 (Gly268Arg) in the AT background in some O alleles11.
We also investigated the molecular genetic basis of Forssman antigen negativity in humans, and found 2 inac-
tivating missense mutations; Ser and Arg at codons 230 and 296, respectively, in the human GBGT1 gene-encoded 
non-functional protein12. Using the DNA transfection assays of African green monkey kidney COS1 cells express-
ing Gb4 as recipients, we showed that the substitution of the Ser to Gly or the Arg to glutamine (Gln), corre-
sponding amino acids of the FSs in Forssman antigen-positive mice and some other species, rendered the human 
protein with weak FS activity whereas the reversion of both conferred strong FS activity. The Arg269Gln reversion 
was later found to be responsible for the activation of GBGT1 gene in rare FORS1 + individuals3.
During species evolution, the GlyGlyAla tripeptide sequence at codons corresponding to 266-268 of human 
AT/BT has been well conserved in the majority of GBGT1 gene-encoded FSs13. We realized that mouse ABO 
gene-encoded cis-AB transferase also possesses the GlyGlyAla sequence14. We then examined whether or not this 
murine enzyme might also exhibit the FS activity by transfecting the expression construct into COS1(B3GALNT1) 
cells expressing transduced human B3GALNT1 gene cDNA encoding β1,3-N-acetyl-d-galactosaminyltransferase 
1 to increase Gb4 content. We observed the appearance of FORS1, whereas human cis-AB transferase with 
LeuGlyAla tripeptide did not exhibit such activity15. We also detected weak FS activity of the modified human 
AT, whose LeuGlyGly was replaced with GlyGlyAla. Those results demonstrated that the GlyGlyAla sequence is 
important for the FS activity, but that this substitution is not sufficient to provide human AT with full FS activity. 
We, therefore, initiated the search for additional molecular mechanisms that would allow ATs to catalyze the 
FORS1 biosynthesis. We found that the deletion of exon 3 or 4, but not of exon 2 or 5, of human AT transcripts 
bestowed moderate FS activity16, indicating that the A allele is inherently capable of producing a protein with FS 
activity. Because altered RNA splicing is frequent in cancer, this mechanism may explain, at least partially, the 
FORS1 appearance in some cancer cells/tissues of regular individuals in the Forssman antigen-negative human 
species17–23. Additionally, we also serendipitously observed that the methionine to serine/threonine substitutions 
at codon 69 (Met69Ser/Thr) conferred weak FS activity24. Furthermore, co-introduction of one of those deletions 
or Met69Ser/Thr substitutions with the LeuGlyGly266-268GlyGlyAla substitution strengthened FS activity, pos-
sibly by the synergistic effects of altered intra-Golgi localization and/or protein conformation by the former and 
modified enzymatic specificity by the latter.
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Figure 1. Schematic representation of biosynthetic pathways of blood group A, B, and FORS1 antigens. The 
biosynthetic pathways of blood group A, B, and FORS1 antigens and related glycans are schematically shown. 
The names of genes, transferases, glycans, and antigens are shown in purple, green, blue, and brown colors, 
respectively. Important genes/transferases/glycans are shown in bold type. Immunodominant epitopes of A, B, 
and FORS1 are shown in red color and bold type.
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In the present study we have generated the COS1(B3GALNT1 + A4GALT) cells expressing transduced human 
A4GALT gene cDNA encoding α1,4-galactosyltransferase, in addition to the human B3GALNT1 gene cDNA 
encoding β1,3-N-acetyl-d-galactosaminyltransferase 1, in order to further improve the detection sensitivity of 
FS activity. We have also substituted the methionine residue at codon 69 of the human AT by any one of the other 
19 amino acids, with and without the GlyGlyAla substitution, and examined the FS activity of those encoded 
proteins by DNA transfection and immunological detection of FORS1. Here, we report differential FS activity of 
the ATs with a missense mutation at codon 69. We also present our surprising finding that the original human AT 
may also catalyze the FORS1 biosynthesis under certain circumstances.
Results
Methionine is conserved at codons corresponding to 69 of human AT/BT of the ABO gene-en-
coded proteins in a variety of species, but not of the GBGT1 gene-encoded proteins. The 
ABO, GBGT1, A3GALT2, GGTA1, and GLT6D1 genes are paralogous genes evolved from the same ancestral 
gene13,25,26. While it remains to be determined whether the GLT6D1 gene-encoded proteins may have glyco-
syltransferase activity or not, the functional genes in the first 4 categories encode proteins with glycosylation 
functions: ATs/BTs, FSs, isoglobotriaosylceramide synthases (iGb3Ss) to synthesize isoglobotriaosylceramide 
(iGb3: Galα1-3Galβ1-4Glcβ1-1’Cer), and α1,3-galactosyltransferases (GTs) to synthesize the α1,3-galactosyl 
epitope (α-Gal-epitope: Galα1-3Galβ1-4GlcNAcβ-). All those glycosyltransferase genes have sequence homol-
ogy in the last 2 coding exons, whereas the genes encoding ATs/BTs and FSs are homologous in the last 3 
coding exons.
Codon 69 of human AT/BT is located at the beginning of exon 5, the 3rd coding exon from the last. In order to 
compare amino acid residues at codons corresponding to 69 of human AT/BT, we used the CLUSTALW aligned 
amino acid sequences of proteins encoded by the ABO and GBGT1 gene orthologs from various species (Gene 
Tree: ENSGT00950000182858). As shown in Table 1, they are methionines in the ABO genes in a variety of spe-
cies. Although there are species with other amino acids at that position, they are a minority. Because the methio-
nine residue is present over phylogenetic boundaries from amphibians to mammals and to primates, it seems to 
be the prototype in the ABO genes. On the other hand, the methionine residue was rarely present at that position 
in the GBGT1 genes although it was coincidentally found in mangrove killifish. Therefore, the methionine residue 
at that position differentiates well between the ABO and GBGT1 gene-encoded proteins.
COS1(B3GALNT1 + A4GALT) cells expressing human B3GALNT1 gene-encoded β1,3-N-acetyl-d- 
galactosaminyltransferase 1 and human A4GALT gene-encoded α1,4-galactosyltransferase 
were generated. Previously, we prepared COS1(B3GALNT1) cells by transduction of African green 
monkey kidney COS1 cells with the retroviral vector to express human B3GALNT1 gene cDNA encoding 
β1,3-N-acetyl-d-galactosaminyltransferase 115. Use of those cells as a host for DNA transfection somewhat 
improved the detection sensitivity of FS activity15. However, thin-layer chromatography (TLC) analysis of 
the neutral glycosphingolipid (nGSL) fraction isolated from COS1(B3GALNT1) cells revealed low globo-
side (Gb4) content in spite of that manipulation, as shown in lane 2 of the left panel in Fig. 2. It also showed 
that lactosylceramide (LacCer) was abundant but globotriaosylceramide (Gb3) was not. Because LacCer is 
the precursor of Gb3, we hypothesized that weak activity of α1,4-galactosyltransferase, which is also called 
as Gb3 synthase, might be the rate-limiting factor of Gb4 synthesis. Due to insufficient Gb3 substrates, 
β1,3-N-acetyl-d-galactosaminyltransferase 1 may not synthesize Gb4 efficiently even when the transduced gene 
is expressed in those cells. Therefore, we further transduced COS1(B3GALNT1) cells with the retroviral vec-
tor encoding human α1,4-galactosyltransferase, and generated COS1(B3GALNT1 + A4GALT) cells expressing 
both β1,3-N-acetyl-d-galactosaminyltransferase 1 and α1,4-galactosyltransferase. As shown in lane 3 of the left 
panel in Fig. 2, the newly created cells produced an enhanced level of Gb4. However, we also observed weaker 
bands of larger sizes than Gb4. In order to exclude the possibility that those extra bands are of Forssman gly-
colipid (Gb5), we performed direct immunostaining of nGSLs from COS1(B3GALNT1 + A4GALT) cells on 
TLC using anti-FORS1 antibody. For comparison, nGSLs isolated from COS1(B3GALNT1 + A4GALT) cells 
that were transduced with mouse GBGT1 gene cDNA encoding functional FS, COS1(B3GALNT1 + A4GALT 
+ mGBGT1) cells, was applied in parallel. Results of immunostaining are shown in the right panel of Fig. 2. 
Gb5 carrying FORS1 antigen was found present in nGSLs isolated from COS1(B3GALNT1 + A4GALT + m
GBGT1) cells (lane C), but not from COS1(B3GALNT1 + A4GALT) cells (lane 3). We, therefore, concluded 
that COS1(B3GALNT1 + A4GALT) cells expressing increased Gb4 might be useful to detect FS activity with 
improved sensitivity.
(A). Species possessing the methionine in the ABO gene-encoded proteins
Xenopus frog, painted turtle, Agassiz’s desert tortoise, elephant, horse, donkey, cat, red fox, microbat, dog, dingo, polar bear, American black 
bear, panda, rat, Chinese hamster, Northern American deer mouse, Upper Galilee mountains blind mole rat, kangaroo rat, rabbit, pika, mouse 
lemur, Coquerel’s sifaka, tarsier, capuchin, marmoset, crab-eating macaque, macaque, sooty mangabey, drill, vervet African green monkey 
(vervet-AGM), olive baboon, Black snub-nosed monkey, bonobo, and human
(B). Species possessing the methionine in the GBGT1 gene-encoded proteins
Mangrove killifish
Table 1. Species possessing the methionine residue at codons corresponding to 69 of the human AT/BT in the 
ABO and GBGT1 gene-encoded proteins.
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Human A transferase (AT) expression constructs containing any amino acid substitution at 
codon 69 with and without the LeuGlyGly266-268GlyGlyAla substitution were prepared. We 
performed primer-mediated in vitro mutagenesis to prepare human AT amino acid substitution constructs at 
codon 69 with and without the LeuGlyGly266-268GlyGlyAla substitution. We obtained many, but not all, of the 
constructs by two-round polymerase chain reactions (PCRs) using degenerate oligonucleotide primers. To obtain 
those missing, we utilized specific oligonucleotide primers designed to introduce the corresponding mutations. 
In the end, we successfully obtained all the forty constructs with any one of 20 possible amino acids at codon 69 
and 2 constructs with the translation termination codon (Ter) at that position. Amino acid residues at important 
codons and other characteristics of the expression constructs used in this study are listed in Table 2.
Various amino acid substitutions at codon 69 of human AT conferred FS activity of differential 
strength. Using COS1(B3GALNT1 + A4GALT) cells as recipients, transient transfection experiments were 
performed with DNA from the AT or its mutant constructs and DNA from the pEGFP plasmid vector express-
ing enhanced green fluorescent protein (GFP), followed by monitoring GFP-positive (GFP+) cells under the 
fluorescence microscope to estimate transfection efficiency and immunocytochemical detection of the FORS1 
expression.
The results of AT substitution constructs containing an amino acid substitution at codon 69 without the 
LeuGlyGly266-268GlyGlyAla substitution are shown in Fig. 3. The positive control constructs of mouse GBGT1 
and ABO genes, M_GBGT1 and M_ABO-AB, respectively, exhibited strong FORS1 antigen expression, whereas 
the “No DNA” control presented a negative result. The B allele construct of the human ABO gene, H_ABO-B, 
also gave a negative result. As previously reported16, the human AT constructs containing the deletion of exon 3 
or 4 in combination with the LeuGlyGly266-268GlyGlyAla substitution, H_ABO-A(delEx3 & GlyGlyAla) and 
H_ABO-A(delEx4 & GlyGlyAla), strongly expressed FORS1 antigen. The human AT constructs containing an 
amino acid substitution at codon 69 exhibited differential expression of FORS1 antigen, depending on which 
amino acid substituted. Surprisingly, the original A allele construct of the human ABO gene, H_ABO-A, as well 
as the methionine construct, H_ABO-A(Met69Met), having the same amino acid sequence as H_ABO-A con-
struct also exhibited the FORS1 expression although the activity was the lowest. The H_ABO-A(Met69Ile) and 





















































































Figure 2. Thin-layer chromatography (TLC) analysis of neutral glycosphingolipids isolated from COS1 and 
derivative cells. The orcinol staining panel shows nGSLs as purple bands. Lane S corresponds to the standards: 
lactosylceramide (LacCer), globotriaosylceramide (Gb3) and gangliotetraosylceramide (asialo-GM1, GA1). 
Samples are nGSLs isolated from COS1, COS1(B3GALNT1), and COS1(B3GALNT1 + A4GALT) cells for 
lanes 1-3, respectively. The bands are marked, and their simplified molecular structures are shown on the 
left. GlcCer is glucosylceramide, Gb4 corresponds to globoside, and the asterisk indicates an orange band of 
a lipid not containing glycans. Another TLC plate containing nGSLs from COS1(B3GALNT1 + A4GALT) 
cells (lane 3) and nGSLs from those cells transduced with mouse GBGT1 gene cDNA encoding FS, 
COS1(B3GALNT1 + A4GALT + mGBGT1) (lane C), was subjected to direct immunostaining using anti-
FORS1 antibody. The FORS1-carrying Gb5 bands are marked, together with the simplified molecular structure 
of Gb5 on the right. The application locations and final solvent front are also indicated.
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low FS activities, whereas the construct with the translation termination codon, H_ABO(Met69Ter), expressed 
no FORS1 antigen.
In order to take microphotographs of cells immunostained with anti-FORS1 antibody after DNA transfection, 
we performed another immunocytochemistry experiment of selected constructs, using chambered cell culture 
slides. Figure 4a shows the results of human AT derivative constructs containing Cys, Asp, Ile, Leu, Met, Arg, and 
Ter at codon 69, H_ABO-A(Met69Cys), H_ABO-A(Met69Asp), H_ABO-A(Met69Ile), H_ABO-A(Met69Leu), 
H_ABO-A(Met69Met), H_ABO-A(Met69Arg), and H_ABO-A(Met69Ter), as well as mouse FS and human AT 
and BT constructs, M_GBGT1, H_ABO-A, and H_ABO-B, respectively.
Amino acid substitutions at codon 69 of the human AT did not affect much of the AT activity. 
The AT activity was examined of the human AT amino acid substitution constructs at codon 69 by DNA trans-
fection into HeLa(FUT2) cells followed by the immunocytochemical detection of A antigen. Strong AT activity 
was present for all those human AT constructs with an amino acid substitution at codon 69 (data not shown). 
In order to take the microphotographs of HeLa(FUT2) cells immunostained with anti-A antibodies after DNA 
transfection, we also performed another immunocytochemistry experiment using chambered cell culture slides. 
The same set of constructs used above with COS1(B3GALNT1 + A4GALT) cells were transfected to HeLa(FUT2) 
cells. Results are shown in Fig. 4b.
Construct Name
Amino acid residue at codon
Additional change(s)69 266 267 268
H_ABO-A Met Leu Gly Gly
H_ABO-B Met Met Gly Ala Arg176Gly, Gly235Ser
M_GBGT1 Leu Gly Gly Ala Different gene Many more
M_ABO-AB Asn Gly Gly Ala Different gene Many more
H_ABO-A(delEx3 & GlyGlyAla) Met Gly Gly Ala Exon 3 deletion
H_ABO-A(delEx4 & GlyGlyAla) Met Gly Gly Ala Exon 4 deletion
H_ABO-A(Met69Xxx) Xxx (Various) Leu Gly Gly
H_ABO-A(Met69Xxx & GlyGlyAla) Xxx (Various) Gly Gly Ala
Table 2. Amino acid residues at important codons and other changes of the expression constructs used in the 
study.
Figure 3. FORS1 antigen expression after DNA transfection of a variety of human AT amino acid substitution 
constructs at codon 69 into COS1(B3GALNT1 + A4GALT) cells analyzed by immunocytochemistry. The 
averages and standard deviations of FORS1 + cells are shown of the cells transfected with human AT amino 
acid substitution constructs at codon 69, H_ABO-A(Met69Xxx). “No DNA” without sample DNA was 
used as a negative control, and M_GBGT1 and M_ABO-AB constructs encoding mouse FS and cis-AB 
transferases, respectively, were used as positive controls. The H_ABO-A and H_ABO-B encode human AT 
and BT, respectively. The H_ABO-A(delEx3 & GlyGlyAla) and H_ABO-A(delEx4 & GlyGlyAla) represent the 
constructs with the deletion of exon 3 or 4 in combination with the LeuGlyGly266-268GlyGlyAla substitution, 
respectively. All the amino acid substitution constructs at codon 69 are shown by the substituted amino acid 
names in the one-letter and three-letter codes.
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Figure 4. Microphotographs of COS1(B3GALNT1 + A4GALT) cells immunostained with the anti-FORS1 
antibody and those of HeLa(FUT2) cells immunostained with anti-A antibodies after DNA transfection with 
the selected human AT derivative constructs. (a) COS1(B3GALNT1 + A4GALT) cells were transfected with the 
selected human AT derivative constructs and immunostained with clone FOM-1 rat anti-FORS1 antibody. The 
cells were next incubated with the biotinylated anti-rat IgG + IgM(H + L) secondary antibody followed by the 
Vectastain ABC reagents treatment and DAB color development. The “No DNA” corresponds to cells without 
DNA transfection. The constructs transfected are: M_GBGT1, H_ABO-A, H_ABO-B, H_ABO-A(Met69Cys), 
H_ABO-A(Met69Asp), H_ABO-A(Met69Ile), H_ABO-A(Met69Leu), H_ABO-A(Met69Met), H_ABO-
A(Met69Arg), and H_ABO-A(Met9Ter). The transfected DNA is indicated above each image. All the images 
were taken with the same settings. The bar corresponds to 100 μm, (b) HeLa(FUT2) cells were transfected with 
the same set of human AT derivative constructs and immunostained with mouse anti-A BioClone antibodies, 
next with the biotinylated goat anti-mouse IgM secondary antibody, followed by the ABC reagents incubation 
and DAB color development. All the images were taken with the same settings. The bar corresponds to 100 μm.
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Enhanced intra-cellular globoside (Gb4) availability of the recipient cells of DNA transfection 
significantly influences the observed FS activity. In addition to the immunocytochemical detec-
tion, we have also examined the expression of the FORS1 antigen by cytometry, and obtained more quantitative 
data. In this set of experiments, we utilized COS1 cells and two related sublines of cells, COS1(B3GALNT1) 
and COS1(B3GALNT1 + A4GALT). We used above-selected 7 human AT derivative constructs, together with 
mouse FS construct, M_GBGT1, as a positive control. DNA from pLL3.7-mRFP plasmid vector encoding mon-
omeric red fluorescent protein (mRFP) was co-transfected to examine the transfection efficiency. After immu-
nostaining of DNA-transfected cells with anti-FORS1 antibody, the total numbers of gated cells, mRFP-positive 
(mRFP+) cells, and the Alexa Fluor 647 dye-positive (AF647+) cells expressing FORS1 antigen were counted, 
and the FORS1+ cell percentages were then calculated after normalization. Results are shown in Fig. 5. Highest 
FORS1 antigen expression was generally observed of the COS1(B3GALNT1 + A4GALT) cells, next with 
COS1(B3GALNT1) cells, and the lowest with COS1 cells, as anticipated from the abundance of acceptor sub-
strate Gb4. The variations in FS activity among the constructs were more evident when the Gb4 availability was 
restricted. On the contrary, FS activity of the original AT encoded by H_ABO-A(Met69Met) was obvious when 
sufficient Gb4 substrates were available in the recipient cells of DNA transfection.
FS activity of the codon 69 amino acid substitution constructs was significantly enhanced by 
the concomitant LeuGlyGly266-268GlyGlyAla substitution. The results of immunocytochemistry 
experiments after transfection of DNA from AT substitution constructs containing an amino acid substitution at 
codon 69 and the LeuGlyGly266-268GlyGlyAla substitution into COS1(B3GALNT1 + A4GALT) cells are shown 
in Fig. 6. Similar to the results of DNA transfection with the human AT constructs without the LeuGlyGly266-
268GlyGlyAla substitution described above, the positive and negative controls presented anticipated positive and 
negative results. In addition, the amino acid substitution constructs at codon 69 exhibited substantially higher 
FORS1 antigen expression when combined with the LeuGlyGly266-268GlyGlyAla substitution, possibly due 
to the synergistic effects previously reported of the AT constructs containing the deletion of exon 3 or 4, or 
Met69Ser/Thr substitution in combination with the LeuGlyGly266-268GlyGlyAla substitution16,24. However, the 
Ter construct, H_ABO-A(Met69Ter & GlyGlyAla), did not present any FS activity even with the LeuGlyGly266-
268GlyGlyAla substitution.
Discussion
In our previous studies utilizing COS1(B3GALNT1) cells as DNA transfection recipients, we showed that the 
Met69Ser/Thr or LeuGlyGly266-268GlyGlyAla substitution of the human AT, or the deletion of exon 3 or 4 of 
the human AT mRNA resulted in the generation of proteins with the FS activity16,24. We have also shown that the 
Met69Ser/Thr substitution or exon 3 or 4 deletion may have a synergistic effect to enhance the FS activity when 
combined with the LeuGlyGly266-268GlyGlyAla substitution, possibly due to the changes in protein conforma-
tion/localization by the former and the changes in sugar specificity by the latter. The present study demonstrated 
that the human ATs with any other amino acid residues than Ser or Thr at codon 69 also manifest FS activity. 
The activity also increased by combining with the LeuGlyGly266-268GlyGlyAla substitution. The use of newly 
generated COS1(B3GALNT1 + A4GALT) cells has drastically improved the sensitivity of FS activity detection. 
The AT construct with methionine also showed FS activity although it was the lowest among all the amino acid 
substitution constructs at codon 69. The conserved methionine residue at the corresponding positions in a variety 
of species in the ABO gene-encoded proteins, but not in the GBGT1 gene-encoded proteins, seems to support the 
Figure 5. Expression of FORS1 antigen after DNA transfection of the selected human AT amino acid 
substitution constructs at codon 69 into COS1, COS1(B3GALNT1), and COS1(B3GALNT1 + A4GALT) 
cells analyzed by cytometry. African green monkey kidney COS1 cells and their derivative sublines of 
COS1(B3GALNT1) and COS1(B3GALNT1 + A4GALT) cells were separately transfected with the selected 
human AT derivative constructs, immunostained with the anti-FORS1 antibody followed by cytometry. The 
averages and standard deviations of FORS1 + cell percentages among the gated cells are shown of individual 
constructs in a bar graph. The secondary antibody only “2nd Ab only” and “Empty” samples were used as 
negative controls.
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hypothesis that this substitution to methionine may have contributed to the separation of ABO genes from the 
GBGT1 genes during the gene evolution after duplication.
There were several distinctions in the experimental procedures between immunocytochemistry and cytom-
etry. Cells were fixed 3 days after DNA transfection in the immunocytochemical detection, whereas cells were 
immunostained directly without fixation 2 days after DNA transfection in the cytometry. The primary and sec-
ondary antibodies were used in the former, whereas an additional fluorescent dye (AF647)-tagged Streptavidin 
was used in the latter. However, the signal was also amplified by the peroxidase mediated enzymatic reaction in 
the former, which may have saturated signals with several constructs in the immunocytochemistry experiments.
The results reminded us of the importance of precursor substrate availability in analyzing the glycosyl-
transferase activity. It was evident in the in vitro enzymatic assays where different quantity of substrates may be 
included in the reactions. However, it has also proven to be correct even in cellular assays employing DNA trans-
fection. As opposed to peptide/protein antigens of RBCs, glycan antigens are not primary gene products. Rather, 
they are the enzymatic reaction products catalyzed by specific glycosyltransferases. In the Michaelis–Menten 
kinetics, the reaction velocity υ (rate of formation of product [P]) is proportional to the concentration of a sub-
strate [S] as indicated by the Michaelis-Menten equation: υ = d[P]/dt = Vmax[S]/(KM + [S]), where Vmax represents 
the maximum rate achieved at saturating substrate concentration and the Michaelis constant KM is the substrate 
concentration at which the reaction rate is half of Vmax. Therefore, in the glycosylation reactions to produce RBC 
glycan antigens, the reaction velocity is dependent on the substrate concentration, whereas the Vmax and KM 
values are unique to individual enzymes. Our results demonstrate that the ordinary human AT may synthesize 
FORS1 under certain conditions where a sufficient concentration of Gb4 substrate is achieved. This may suggest 
that the FS activity may also be induced of the human AT when intra-Golgi concentration of another substrate, 
donor nucleotide sugar UDP-GalNAc, is elevated. In addition to the deletion of exon 3 or 4 of the human AT 
mRNAs we previously identified, the altered availability of donor and/or acceptor substrates may also account for 
an additional molecular mechanism that enables the human AT to express genetically inappropriate heterophilic 
FORS1 antigen in cancer cells/tumor tissues of ordinary individuals.
Gb3 and Gb4 are also called as Pk and P, and those expressed on RBCs are antigens of the P blood group sys-
tem. α1,4-galactosyltransferase (Gb3 synthase, Pk synthase) encoded by functional A4GALT gene catalyzes the 
conversion of LacCer to Gb3 (Pk). When this gene is mutated by the C > G substitution at nucleotide 631 resulting 
in the Gln to glutamic acid (Glu) substitution at codon 211, the α1,4-galactosyltransferase specificity is altered, 
and a rare inheritable NOR polyagglutination syndrome is manifested27,28. Additional Galα1-4-, GalNAcβ1-
3Galα1-4-, and Galα1-4GalNAcβ1-3Galα1-4- structures may be linked to the non-reducing terminal GalNAc 
residue of Gb4, and globoside derivatives, NOR1, NORint, and NOR2, are synthesized, respectively29,30. In spite of 
the fact that additional bands appeared in TLC analysis of nGSLs isolated from COS1(B3GALNT1 + A4GALT) 
cells, the A4GALT gene cDNA we used to generate those cells had an identical sequence to the reference 
NM_017436.4. Accordingly, those bands may not represent such Gb4 derivatives.
In this study we have demonstrated the FS activity of the human AT and its codon 69 substitutions constructs 
by improving the Gb4 substrate availability and the detection sensitivity. However, it should be mentioned that 
the enhancement is rather artificial. Several dozens of different types of tissues and 200 to 400 distinct types of 
cells are present in the human body. And individual cells/tissues may manifest unique expression profiles of 
glycosyltransferases and/or glycosidases. Accordingly, the results would have been entirely different if hemato-
poietic cells were used, in place of epithelial cells of COS1 cells and HeLa cells, in the experiments. There are other 
Figure 6. FORS1 antigen expression after DNA transfection of a variety of human AT amino acid substitution 
constructs at codon 69 with the LeuGlyGly266-268GlyGlyAla substitution into COS1(B3GALNT1 + A4GALT) 
cells analyzed by immunocytochemistry. The human AT amino acid substitution constructs at codon 69 with 
the LeuGlyGly266-268GlyGlyAla substitution, H_ABO-A(Met69Xxx & GlyGlyAla), were examined for the 
FS activity. See the Fig. 3 legend for the detailed information of those constructs except the LeuGlyGly266-
268GlyGlyAla substitution was added.
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unknowns. For instance, human RBC membranes contain globoside as the prevalent neutral glycosphingolipid. 
Therefore, Gb4 is present at high concentration. In blood group A and AB individuals the AT should be present 
and functional during erythropoiesis leading to RBC differentiation because it produces cell-surface A antigens. 
Nonetheless, no FORS1 is synthesized. Accordingly, there may also be molecular mechanism(s) inhibiting the 
FORS1 biosynthesis in RBCs in FORS1-negative individuals. Such inhibitory mechanisms may need to be eluci-
dated by future studies.
Methods
Preparation of human AT amino acid substitution constructs at codon 69 by in vitro mutagenesis. 
We performed the 2-round PCR using specific primers to introduce amino acid substitutions as previously 
described13,15,24. We used, as templates, H_ABO-A, human AT cDNA expression construct prepared in the pSG5 
eukaryotic expression plasmid vector, and its derivative, H_ABO-A(GlyGlyAla), possessing the LeuGlyGly266-
268GlyGlyAla tripeptide substitution. The detailed protocols are presented in the Supplemental Information.
Generation of COS1(B3GALNT1 + A4GALT) cells. COS1(B3GALNT1 + A4GALT) cells were created from 
COS1(B3GALNT1) cells expressing human B3GALNT1 gene-encoded β1,3-N-acetyl-d-galactosaminyltransferase 
115,24. We employed the glycan customization technology by modular expression of glycosyltransferases, utilizing the 
retroviral pMigR1g-A4GALT construct31. This construct available in the laboratory contained the human A4GALT 
gene cDNA followed by an internal ribosome entry site (IRES) element and then cDNA encoding enhanced GFP in 
the pMigR1g retroviral vector. DNA was transfected into Phoenix-AMPHO packaging cells, using Lipofectamine 2000 
reagent (Thermo Fisher Scientific) following the manufacturer’s instructions. The culture media containing the viral 
particles were recovered and filtered. COS1(B3GALNT1) cells were then infected with the viral particles and allowed 
to grow to confluence. After being detached with trypsin/EDTA and re-suspended in culture media, cells expressing 
both the coupled blue and green emitting fluorescent proteins (mTagBFP2 and GFP) were FACS-sorted to generate 
COS1(B3GALNT1 + A4GALT) cells. The selected cells were expanded and used as recipients of DNA transfection.
Isolation and TLC analysis of neutral glycosphingolipids. Neutral glycosphingolipid (nGSL) fractions 
were isolated using the protocol modified from “Extraction of glycolipids by Okino and Ito” in the GlycoPOD 
GlycoScience Protocol Online Database [https://jcggdb.jp/GlycoPOD/protocolShow.action?nodeId=t4]. 
Briefly, cells were grown in 4 plates of 15 cm cell culture dishes. When the cells reached confluence, they were 
PBS-washed, scraped, and harvested. Cell pellets were pooled for each sample by centrifugation. Lipid extrac-
tion was achieved by incubation with chloroform/methanol (2:1 v/v), sonication for 5 min in a sonicator bath 
(Selecta), followed by incubation at 37 °C for 1 h with agitation. After centrifuging (1000 × g, room temperature, 
15 min), the solvent was transferred into a glass tube. The pellet was further extracted with chloroform/methanol/
water (1:1:0.8) at 37 °C for 2 h with agitation. After centrifuging, the solvent was pooled with the first one. The 
total lipids extracted were dried by evaporation at 55 °C and resuspended in 4 ml of methanol. Saponification was 
performed by adding 50 µl of 4 M NaOH and incubating the sample at 37 °C for 2 h followed by neutralization 
with 50 µl of 4 M acetic acid. Then, 4 ml of water were added and the mixture was loaded onto Oasis H1B puri-
fication columns (reverse-phase cartridge, Waters Corp). After washing with methanol/water (1:1) and water, 
the glycosphingolipid fraction was eluted using methanol. The glycolipids were again dried by evaporation and 
resuspended in 4 ml of methanol followed by the addition of water. The resulting mix was loaded onto Oasis MAX 
columns (anion exchange cartridge, Waters Corp.). After methanol/water (1:1) and water washes, nGSLs were 
eluted with methanol whereas acidic GSLs (containing sialic acid) remained bound to the column. After drying, 
the glycolipids were resuspended in chloroform/methanol (1:1).
20 μl of nGSLs from COS1, COS1(B3GALNT1) and COS1(B3GALNT1 + A4GALT) cells were applied onto 
a TLC aluminum foil plate, together with the mixture of 2.5 μg each of lactosylceramide, globotriaosylceramide 
and gangliotetraosylceramide (asialo-GM1)(all from Sigma) on the “Standards” lane. After 30 min, the plate was 
placed in a chromatographic chamber containing chloroform/methanol/water (65:35:8). The ascending solvent 
separated lipids. When the front reached approximately 1 cm to the edge, the plate was retrieved from the cham-
ber and allowed to dry. The plate was then sprayed with orcinol (Sigma) diluted in sulfuric acid and heated at 
110 °C until purple bands became visible.
We performed direct immunostaining of nGSLs separated on TLC plate. 10 μl each of nGSLs from 
COS1(B3GALNT1 + A4GALT) and COS1(B3GALNT1 + A4GALT + mGBGT1) cells were applied and chro-
matographed as explained above. After drying, the plate was blocked and hydrated with 5% non-fat dry milk 
in Tris-buffered saline plus 0.05% Tween 20 (TBST) for 16 h. It was then incubated with clone FOM-1 rat IgM 
monoclonal anti-FORS1 antibody (Bio-Rad Antibodies) diluted at 1/1000 in the same solution for 3 h at room 
temperature. Following the TBST washes, the plate was incubated with rabbit anti-rat IgG + IgM + IgA H&L 
(HRP) antibody (Abcam) at 1/10000 dilution for 1 h at room temperature. It was then washed and incubated with 
ECLTM Detection Reagents (Sigma). After exposure, the chemiluminescence-sensitive film (BD) was developed 
using an automated FUJI Medical Film FPM100A processor.
Immunocytochemical detection of FORS1 antigen expression after transient DNA transfection 
of COS1(B3GALNT1 + A4GALT) cells and of blood group A antigen expression after DNA trans-
fection of HeLa(FUT2) cells. Newly generated COS1(B3GALNT1 + A4GALT) cells were used as recipients 
of DNA transfection as previously described with COS1(B3GALNT1) cells13,15. Briefly, DNA from the AT or its 
mutant constructs and DNA from the pEGFP plasmid vector expressing enhanced GFP were co-transfected, 
using Lipofectamine 3000 reagent (Thermo Fisher Scientific). Three days after transfection, GFP-positive 
(GFP+) cells were counted under the fluorescence microscope to estimate the variations in transfection effi-
ciency. The transfected cells were dried, fixed with 4% paraformaldehyde in PBS, washed, and then subjected to 
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immunostaining. Clone FOM-1 rat IgM monoclonal anti-FORS1 antibody was used as the primary antibody to 
detect the FORS1 expression. The cells were next treated with a biotinylated goat anti-rat IgG + IgM(H + L) sec-
ondary antibody (Jackson ImmunoResearch Laboratories), PBS washed, and then incubated with the Vectastain 
ABC reagents (Vector Laboratories). 3,3′-diaminobenzidine tetrahydrochloride (DAB) from the same company 
was used for peroxidase-mediated color development. DAB-positive cells were counted under the microscope 
and the numbers were normalized using the numbers of GFP+ cells. The experiments were repeated 6 times for 
all the constructs, and the averages and standard deviations were calculated.
HeLa(FUT2) cells, HeLa derivative cells expressing transduced human FUT2 gene cDNA encoding 
α1,2-fucosyltransferase (H enzyme) to increase H substance, the acceptor substrate for AT/BT, were also used as 
recipients of DNA transfection as previously described13,15. In addition to DNA from the expression constructs, 
DNA from the pEGFP plasmid was co-transfected, using Lipofectamine 3000 reagent. To detect A antigen expres-
sion, cells were immunostained with the mixture of murine anti-A monoclonal antibodies (BioClone, Ortho 
Clinical Diagnostics) as primary antibodies, and biotinylated goat anti-mouse IgM secondary antibody (Vector 
Laboratories). Otherwise, the same immunocytochemical protocols described above were employed.
To take the microphotographs of immunostained cells after DNA transfection, COS1(B3GALNT1 + A4GALT) 
and HeLa(FUT2) cells were seeded on 8-cell Millicell EZ slides (Merck Millipore) previously coated with 10 μg/
ml poly-L-lysine (Merck). When cells reached to 70–90% confluence, they were transfected using Lipofectamine 
3000. 3 days after transfecton, cells were fixed with 4% paraformaldehyde, rinsed with PBS, and immunostained 
as described above. After color development, DAB was removed, and cells were washed with water and PBS. 
The incubation chambers were removed, and the slides were treated with 95% ethanol and air-dried. The slides 
were mounted with Vectamount medium (Vector Laboratories) and then with glass coverslips (Erie Scientific 
Company). Cells were imaged using a DMI6000B microscope equipped with color camera DFC420 and LAS X 
software (Leica). Images were corrected for brightness and contrast using Adobe Photoshop CS5, and figures were 
generated using Adobe Illustrator CS5.
Transient DNA transfection of expression constructs, FORS1 immunostaining, and cytometry 
of COS1, COS1(B3GALNT1), and COS1(B3GALNT1 + A4GALT) cells. COS1, COS1(B3GALNT1) 
and COS1(B3GALNT1 + A4GALT) cells were transfected with DNA from the selected expression constructs, 
using Lipofectamine 3000. DNA from pLL3.7-mRFP plasmid vector encoding mRFP was co-transfected to be 
used as efficiency control marker. After 48 h, cells were detached from culture plates with 5 mM EDTA in PBS 
and subjected to immunostaining, first with the primary FOM-1 anti-FORS1 antibody, then with the bioti-
nylated goat anti-rat IgG + IgM(H + L) secondary antibody, and finally with AF647-conjugated Streptavidin 
(Thermo Fisher Scientific). A BD LSRFortessa Analyzer (BD Biosciences) was used for cytometry, employing 
the same settings for a single set of experiments. Viable single cells were gated based on their forward and side 
scattering values. Positive fluorescence of mTagBFP2-encoded blue fluorescent protein (BFP) was also used for 
gating the COS1(B3GALNT1) cells, whereas positive fluorescence of GFP and BFP was used for selecting the 
COS1(B3GALNT1 + A4GALT) cells. Fluorescence was measured at 575 nm to identify co-transfected mRFP 
expression and to determine the transfection efficiency. FORS1 expression was detected by AF647 fluorescence at 
660 nm. Experiments were repeated three times, and FORS1+ cell percentages were calculated.
Data Availability
The original data that support the findings of this study are available from the corresponding author on reasona-
ble request (fyamamoto@carrerasresearch.org).
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